Spinal fusion using an HMG-CoA reductase inhibitor
View Patent ↗An improved technique for spinal fusion including administration of an HMG-CoA reductase inhibitor to the fusion site. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a noncompressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.
1. A method for promoting spinal fusion, the method comprising the steps of: exposing an upper vertebra and a lower vertebra;
identifying a site for fusion between the upper and lower vertebra;
exposing a bone surface on each of the upper and lower vertebra at the site for fusion;
administering an HMG-CoA reductase inhibitor to the site.
2. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Lovistatin.
3. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Statin.
4. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Simvastatin.
5. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Atorvastatin.
6. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Pravastatin.
7. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is Fuvastatin.
8. The method of claim 1 , wherein the step of administering the HMG-CoA reductase inhibitor further includes the steps of providing the HMG-CoA reductase inhibitor on a carrier and applying the carrier to the site.
9. The method of claim 8 , wherein the carrier is an open cell matrix.
10. The method of claim 9 , wherein the open cell matrix is formed from collagen fibers.
11. The method of claim 10 , wherein the collagen fibers are coated with resorbable hydroxyapatite.
12. The method of claim 8 , further including the step of providing a further compound on the carrier.
13. The method of claim 12 , wherein the compound is an antibiotic.
14. The method of claim 12 , wherein the compound is a pain medication.
15. The method of claim 8 , wherein the carrier is a non-compressible delivery vehicle.
16. The method of claim 15 , wherein the non-compressible delivery vehicle comprises at least one implantation stick for application to the site such that the implantation stick extends lengthwise between the upper and lower vertebrae.
17. The method of claim 1 , wherein the step of administering the HMG-CoA reductase inhibitor includes the step of applying the HMG-CoA reductase inhibitor with a time release drug delivery system.
18. The method of claim 17 , wherein the time release drug delivery system comprises a hydrogel.
19. The method of claim 1 , wherein the step of administering the HMG-CoA reductase inhibitor includes administering 1–10 mg/kg of the HMG-CoA reductase inhibitor to the site.
20. The method of claim 1 , further including the step of providing a bone fusion device to the site.
21. A method for promoting spinal fusion, the method comprising the steps of:
exposing an upper vertebra and a lower vertebra;
identifying a site for fusion between the upper and lower vertebra;
exposing a bone surface on each of the upper and lower vertebra at the site for fusion;
applying an HMG-CoA reductase inhibitor to a carrier;
applying the carrier to one of the exposed bone surfaces at the site.
22. The method of claim 21 , wherein the carrier is a non-compressible delivery vehicle.
23. The method of claim 22 , wherein the non-compressible delivery vehicle comprises at least one implantation stick for application to the site such that the implantation stick extends lengthwise between the upper and lower vertebrae.
24. A method of promoting non-anatomical bone growth between two bony surfaces, the method comprising the steps of:
identifying a site between two bony surfaces where bone growth is desired but does not
naturally occur;
exposing bone at each of the two bony surfaces;
applying an HMG-CoA reductase inhibitor to at least one of the bony surfaces.
25. The method of claim 24 , wherein the step of administering the HMG-CoA reductase inhibitor further includes the steps of providing the HMG-CoA reductase inhibitor on a carrier and applying the carrier to the site.
26. The method of claim 25 , wherein the carrier is a non-compressible delivery vehicle.